Physician profile
Siraj Abdullah
NPI 1235450685
$1,098.96
in general payments reported to CMS, 2019-2025
17 companies · $572 in 2025
The $572 reported for 2025 was more than what 84% of Sports Medicine (Family Medicine) providers received nationally (typical 2025 total: $113).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.88 · 2022: $135 · 2023: $181 · 2024: $193 · 2025: $572.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $946.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $946.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $166.15 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $164.60 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $128.37 | 2023-2025 | Vraylar |
| Astrazeneca Pharmaceuticals Lp | $110.56 | 2024-2025 | Airsupra |
| Hydrocision, INC. | $107.22 | 2025 | Tenjet |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.73 | 2022-2023 | Jardiance |
| Pfizer INC. | $60.80 | 2024-2025 | |
| Glaxosmithkline, LLC. | $42.83 | 2024 | Trelegy Ellipta, Arexvy |
| Mylan Specialty L.P. | $34.44 | 2024 | Yupelri |
| Exact Sciences Corporation | $34.05 | 2025 | Cologuard Collection Kit |
| Verona Pharma, INC. | $32.67 | 2025 | Ohtuvayre |
| Amgen INC. | $30.92 | 2023-2024 | Otezla, Repatha |
| Viatris Specialty LLC | $19.31 | 2025 | Yupelri |
| Sumitomo Pharma America, INC. | $18.12 | 2025 | Gemtesa |
| Janssen Biotech, INC. | $17.88 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $16.13 | 2025 | Keveyis |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.18 | 2025 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Siraj Abdullah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.